At LeMaitre, we've dedicated our lives to innovation and research to create tools for the vascular surgeon of today and tomorrow.
Location: United States, Massachusetts, Burlington
Investors 1
| Date | Name | Website |
| - | Housatonic... | housatonic... |
Mentions in press and media 14
| Date | Title | Description |
| 03.03.2023 | LeMaitre to Participate at Upcoming Investor Conferences in March | BURLINGTON, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. LMAT announced today that management will be participating in four upcoming investor conferences in March. 35th Annual Roth Conference 2023 Monday, March 13, 2023... |
| 14.07.2021 | LeMaitre Announces Pricing of Public Offering of Common Stock | BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced the pricing of an underwritten public offering of 1,000,000 shares... |
| 13.07.2021 | LeMaitre Provides Q2 2021 Update | BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced preliminary unaudited results for the quarter ended June 30, 2021.... |
| 13.07.2021 | LeMaitre Vascular : Provides Q2 2021 Update (Form 8-K) | LeMaitre Provides Q2 2021 Update BURLINGTON, Mass., July 13, 2021 - LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced preliminary unaudited results for the quarter ended... |
| 18.08.2014 | LeMaitre pays $7.7M for Xenotis and its bio-graft | LeMaitre Vascular (NSDQ:LMAT) got a Wall Street boost today after reporting that it acquired graft-maker Xenotis is a deal valued at $7.7 million. LeMaitre hopes that Xenotis Omniflow II biological graft will make a good complement to its v... |
| 09.05.2012 | Accuray slides on lowered sales outlook | Earnings Roundup | Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012. The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 milli... |
| 18.07.2011 | LeMaitre gets $1.3M in spiking stent graft deal with Endologix | LeMaitre Vascular Inc. (NSDQ:LMAT) officially exited the stent graft market, taking its ball and $1.3 million home after spiking a distribution deal with Endologix Inc. (NSDQ:ELGX) and selling a pair of brands to Duke Vascular. Endologix pa... |
| 18.11.2010 | LeMaitre Vascular buys Lifespan graft from Angiotech for $3 million | LeMaitre Vascular Inc. (NSDQ:LMAT) picked up Angiotech Pharmaceuticals Inc.’s (NSDQ:ANPI) Lifespan vascular graft business for $2.8 million and spiked a distribution deal Angiotech had with former Lifespan owner Edwards Lifesciences Corp. (... |
| 14.10.2010 | LeMaitre Vascular says it will likely close Italian facility | LeMaitre Vascular Inc. (NSDQ:LMAT) might be saying “arrivederci” to its Brindisi, Italy, facility. The Burlington, Mass.-based maker of stents, grafts, carotid shunts, catheters and vascular surgical tools said it is "likely to close&q... |
| 29.07.2010 | Strong Q2 Prompts LeMaitre Vascular to Boost 2010 Guidance | After easily beating Wall Street estimates for the second quarter, LeMaitre Vascular Inc. (Nasdaq:LMAT) is boosting guidance for the rest of 2010. The Burlington, Mass.-based maker of stents, grafts, carotid shunts, catheters and vascular s... |
Show more